Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cedars-Sinai Medical Center
With
Fred Hutchinson Cancer Center
University of Texas
Nara Medical University
University of California, Los Angeles
Nonagen Bioscience Corporation
National Cancer Institute (NCI)
University of Rochester
Nara Prefecture Seiwa Medical Center
Hematuria is the most common presentation of BCa with 22% of patients with gross hematuria harboring BCa. VUC is the most widely used urine-based assay for detecting BCa; however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most curable.
Because of this severe limitation, patients with hematuria (microscopic or gross) will undergo an invasive examination of the urinary bladder, where a miniature camera is inserted into the bladder. We propose to improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with gross hematuria.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or older
Have documented or reported gross hematuria within 3 month of study enrollment
Willing and able to give written informed consent
You may not be if
Have history of BCa
History of previous cancer (excluding basal and squamous cell skin cancer) within the past 3 years
Have a known active urinary tract infection or urinary retention
Have active stone disease (renal or bladder) or renal insufficiency (creatinine \>2.0 mg/dL) Serum creatinine value can be up to 60 days before consent, otherwise repeat
Have ureteral stents, nephrostomy tubes or bowel interposition
Have recent genitourinary instrumentation (within 10 days prior to signing consent)
Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging)